(2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-[4-(2-hydroxypropan-2-yl)phenyl]phenyl]ethyl]amino]pentanamide | 603143-62-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-[4-(2-hydroxypropan-2-yl)phenyl]phenyl]ethyl]amino]pentanamide
• CAS: 603143-62-0
• 化学式: C₂₇H₃₁F₄N₃O₂
• 分子量: 505.556
• InChiKey: UZOUSGTVCLCYMK-VXKWHMMOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  85.2
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-(((S)-2,2,2-trifluoro-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)amino)pentanamide 、 2-羟基-2-(4-溴苯基)丙烷 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 作用下， 生成 (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-[4-(2-hydroxypropan-2-yl)phenyl]phenyl]ethyl]amino]pentanamide
  参考文献：
  名称：

  The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor

  摘要：

  MK-0674 is a potent and selective cathepsin K inhibitor from the same structural class as odanacatib with a comparable inhibitory potency pro. le against Cat K. It is orally bioavailable and exhibits long half-life in pre-clinical species. In vivo studies using deuterated MK-0674 show stereoselective epimerization of the alcohol stereocenter via an oxidation/reduction cycle. From in vitro incubations, two metabolites could be identified: the hydroxyleucine and the glucuronide conjugate which were confirmed using authentic synthetic standards. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.12.083

文献信息

• Cathepsin cysteine protease inhibitors
  申请人：——

  公开号：US20030232863A1

  公开（公告）日：2003-12-18

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  这项发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CATHEPSINE CYSTEINE PROTEASE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2003075836A2

  公开（公告）日：2003-09-18

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  本发明涉及一种新型化合物类别，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，例如骨质疏松症。
• CATHEPSIN CYSTEINE PROTEASE INHIBITORS
  申请人：Bayly Christopher I.

  公开号：US20110230446A1

  公开（公告）日：2011-09-22

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  本发明涉及一种新型化合物类别，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普西林K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• CATHEPSIN CYSTEINE PROTEASE INHIBIORS
  申请人：Merck, Sharp & Dohme, Corp.

  公开号：US20130035312A1

  公开（公告）日：2013-02-07

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  本发明涉及一种新型化合物类别，它们是半胱氨酸蛋白酶抑制剂，包括但不限于，猫hepsins K，L，S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• EP1482924A4
  申请人：——

  公开号：EP1482924A4

  公开（公告）日：2006-03-08